TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation
Go back to TRISCEND II Trial Demonstrates Superior Clinical and Quality-of-life Benefits With Edwards EVOQUE System for Severe Tricuspid Regurgitation| Edwards Lifesciences (NYSE: EW) | Delayed: 89.90 +0.12 (0.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $89.78 | 52 Week High | $166.87 | |||
| Open | $90.21 | 52 Week Low | $72.20 | |||
| Day High | $90.21 | P/E | 26.13 | |||
| Day Low | $88.40 | EPS | $3.44 | |||
| Volume | 2,635,281 | |||||
